| Title |
Low concentration of quercetin antagonizes the invasion and angiogenesis of human glioblastoma U251 cells
|
|---|---|
| Published in |
OncoTargets and therapy, August 2017
|
| DOI | 10.2147/ott.s136821 |
| Pubmed ID | |
| Authors |
Yue Liu, Zhen-Gang Tang, Jian-Quan Yang, Yi Zhou, Ling-Hu Meng, Heng Wang, Cai-Li Li |
| Abstract |
Glioblastoma is the most aggressive type of brain tumor with a very poor prognosis. Therefore, it is always of great importance to explore and develop new potential treatment for glioblastoma. Quercetin, a flavonoid present in a variety of human foods, has been shown to inhibit various tumor cell proliferation. In this study, we found that treating human glioblastoma U251 cells with 10 μg/mL quercetin for 24 hours, a concentration that was far below the IC50 (113.65 μg/mL) and at which quercetin failed to inhibit cell proliferation, inhibited cell migration (30%) and cell invasion as examined by wound scratch assay and transwell assay, respectively. We further showed that 10 μg/mL quercetin inhibited cell migration and tube formation of human umbilical vein endothelial cells induced by the conditioned medium derived from U251 cell culture. The inhibitory effect of quercetin on migration and angiogenesis is possibly mediated through the downregulation of protein levels of VEGFA, MMP9, and MMP2 as detected by Western blot. Our findings demonstrated that low concentration of quercetin antagonized glioblastoma cell invasion and angiogenesis in vitro. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 44 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 44 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 7 | 16% |
| Student > Master | 5 | 11% |
| Student > Doctoral Student | 3 | 7% |
| Student > Postgraduate | 3 | 7% |
| Other | 2 | 5% |
| Other | 7 | 16% |
| Unknown | 17 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 7 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 11% |
| Agricultural and Biological Sciences | 5 | 11% |
| Chemistry | 3 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Other | 2 | 5% |
| Unknown | 20 | 45% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 September 2017.
All research outputs
#17,585,804
of 25,784,004 outputs
Outputs from OncoTargets and therapy
#1,155
of 3,014 outputs
Outputs of similar age
#211,090
of 328,607 outputs
Outputs of similar age from OncoTargets and therapy
#39
of 83 outputs
Altmetric has tracked 25,784,004 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,014 research outputs from this source. They receive a mean Attention Score of 3.0. This one has gotten more attention than average, scoring higher than 51% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 328,607 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 83 others from the same source and published within six weeks on either side of this one. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.